ID   TSU
AC   CVCL_8763
DR   cancercelllines; CVCL_8763
DR   CGH-DB; 360-2
DR   ChEMBL-Cells; CHEMBL3308092
DR   ChEMBL-Targets; CHEMBL613973
DR   Cosmic; 850416
DR   Cosmic; 876397
DR   Cosmic; 930338
DR   Cosmic; 1046038
DR   Cosmic; 1123043
DR   IARC_TP53; 1107
DR   PubChem_Cell_line; CVCL_8763
DR   Wikidata; Q54973168
RX   PubMed=1570156;
RX   PubMed=8704650;
RX   PubMed=10069537;
RX   PubMed=12632084;
RX   PubMed=17052259;
RX   PubMed=17599052;
RX   PubMed=18097548;
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=1570156).
CC   Derived from site: In situ; Oral cavity, gingiva; UBERON=UBERON_0001828.
DI   NCIt; C129857; Gingival squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=1570156;
RA   Sakai E., Tsuchida N.;
RT   "Most human squamous cell carcinomas in the oral cavity contain
RT   mutated p53 tumor-suppressor genes.";
RL   Oncogene 7:927-933(1992).
//
RX   PubMed=8704650; DOI=10.1016/0964-1955(95)00038-0;
RA   Hayashi E., Rikimaru K., Nagayama M.;
RT   "Simultaneous production of G- and M-CSF by an oral cancer cell line
RT   and the synergistic effects on associated leucocytosis.";
RL   Eur. J. Cancer B Oral Oncol. 31:323-327(1995).
//
RX   PubMed=10069537; DOI=10.1111/j.1600-0714.1999.tb02006.x;
RA   Hoteiya T., Hayashi E., Satomura K., Kamata N., Nagayama M.;
RT   "Expression of E-cadherin in oral cancer cell lines and its
RT   relationship to invasiveness in SCID mice in vivo.";
RL   J. Oral Pathol. Med. 28:107-111(1999).
//
RX   PubMed=12632084; DOI=10.3892/ijo.22.4.891;
RA   Yokoyama K., Kamata N., Fujimoto R., Tsutsumi S., Tomonari M.,
RA   Taki M., Hosokawa H., Nagayama M.;
RT   "Increased invasion and matrix metalloproteinase-2 expression by
RT   Snail-induced mesenchymal transition in squamous cell carcinomas.";
RL   Int. J. Oncol. 22:891-898(2003).
//
RX   PubMed=17052259; DOI=10.1111/j.1349-7006.2006.00343.x;
RA   Kozaki K.-i., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H.,
RA   Omura K., Inazawa J.;
RT   "PIK3CA mutation is an oncogenic aberration at advanced stages of oral
RT   squamous cell carcinoma.";
RL   Cancer Sci. 97:1351-1358(2006).
//
RX   PubMed=17599052; DOI=10.1038/sj.onc.1210589;
RA   Suzuki E., Imoto I., Pimkhaokham A., Nakagawa T., Kamata N.,
RA   Kozaki K.-i., Amagasa T., Inazawa J.;
RT   "PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in
RT   oral squamous-cell carcinomas by aberrant promoter hypermethylation.";
RL   Oncogene 26:7921-7932(2007).
//
RX   PubMed=18097548; DOI=10.3892/ijo.32.1.101;
RA   Murugan A.K., Hong N.T., Fukui Y., Munirajan A.K., Tsuchida N.;
RT   "Oncogenic mutations of the PIK3CA gene in head and neck squamous cell
RT   carcinomas.";
RL   Int. J. Oncol. 32:101-111(2008).
//